Chattem Flexes Earnings Guidance After Strong Start For Core Brands
This article was originally published in The Tan Sheet
Executive Summary
Strong sales in January and high expectations for product initiatives planned for the remainder of the year prompted Chattem to increase its fiscal 2008 earnings estimates, the firm's executives told analysts Jan. 29
You may also be interested in...
Chattem To Consider New Icy Hot Heat Therapy Product In Wake Of Recall
Chattem will consider introducing a new version of its Icy Hot Heat Therapy disposable pain patch after voluntarily recalling the current version of the self-heating product, according to the firm
Alli Lifestyle Marketing Plan Could Prompt Copies – Researchers
GlaxoSmithKline's marketing of alli as an addition to a healthy lifestyle and not as the complete solution to consumers' weight-loss needs could prompt other pharmaceutical companies to follow similar marketing plans, according to researchers
Chattem/J&J deal closes
Chattem announces Jan. 2 it closed its agreement to acquire the U.S. rights to ACT, Unisom, Cortizone, Kaopectate and Balmex brands for $410 mil. in cash. The acquired brands were divested in connection with J&J's acquisition of Pfizer's Consumer Healthcare business (1"The Tan Sheet" Dec. 18, 2006, p. 9 and 2"The Tan Sheet" Oct. 9, 2006, p. 6). "We are very excited to add these leading brands to the company's existing portfolio of quality products," Chattem CEO and Chairman Zan Guerry says. In related news, Standard & Poor's says Chattem will replace Fidelity Bankshares in the S&P SmallCap 600 index after the close of trading Jan. 5...